<DOC>
	<DOCNO>NCT00003133</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow surgery treat patient advanced bladder cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Following Surgery Treating Patients With Advanced Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity sequential dose intensive adjuvant systemic therapy consist gemcitabine , doxorubin , follow paclitaxel cisplatin filgrastim ( granulocyte colony stimulate factor ; G-CSF ) patient completely resect , locally advanced transitional cell carcinoma urothelium . II . Assess disease free overall survival patient . OUTLINE : Patients receive gemcitabine IV week 1 , 2 , 3 , 5 , 6 , 7 total 6 dos . A 1 week rest period occur third dose gemcitabine . At least 14 day last dose gemcitabine , ninth week , patient receive doxorubicin 2 week interval ( week 9 , 11 , 13 , 15 ) total 4 dos . Filgrastim ( granulocyte colony stimulate factor ; G-CSF ) administer subcutaneously day 3-10 cycle doxorubicin . At least 14 day last dose doxorubicin , week 17 , patient receive combination paclitaxel IV ( 3 hour infusion ) cisplatin , 2 week interval ( week 17 , 19 , 21 , 23 ) total 4 dos . G-CSF administered day 3-10 cycle . Patients follow every 3 month first 2 year , every 6 month next 3 year , annually death . PROJECTED ACCRUAL : This study accrue 25-30 patient 1.5-2 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically prove complete resection locally advance transitional cell carcinoma urothelium negative margin Disease extend beyond bladder , ureter , regional lymph node Stages eligible patient bladder cancer : Tany , N+ , M0 T3b , N0 , M0 T4a , N0 , M0 Stages eligible patient urothelial cancer renal pelvis ureter : Tany , N+ , M0 T3 , N0 , M0 T4 , N0 , M0 Local control primary urothelial tumor obtain : Cystoprostatectomy plus pelvic lymph node dissection bladder cancer male Cystectomy/TAH/BSO pelvic lymph node dissection bladder cancer females Nephroureterectomy disease involve renal pelvis ureter PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % ECOG 01 Life expectancy : Not specify Hematopoietic : Platelet count least 150,000/mm3 Granulocyte count least 1500/mm3 Hepatic : Bilirubin le 1.5 time normal SGOT alkaline phosphatase less 2 time normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 60 mL/ min Cardiovascular : LVEF least 50 % No New York Heart Association class II IV heart disease No serious cardiac arrhythmia , include first , second , third degree heart block Other : No concurrent second malignancy except nonmelanomatous skin cancer curatively treat situ carcinoma cervix No uncontrolled infection Fertile patient must use barrier method contraception , , 6 month therapy encourage continue barrier method contraception 2 year longer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior irradiation bladder Surgery : See Disease Characteristics Definitive surgery perform within 10 week study treatment start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>